NK Cell Lectin-Like Receptor Subfamily B
"NK Cell Lectin-Like Receptor Subfamily B" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of NK cell lectin-like receptors that includes both inhibitory and stimulatory members.
| Descriptor ID |
D055651
|
| MeSH Number(s) |
D12.776.543.750.705.895.800.200
|
| Concept/Terms |
NK Cell Lectin-Like Receptor Subfamily B- NK Cell Lectin-Like Receptor Subfamily B
- NK Cell Lectin Like Receptor Subfamily B
- Killer Cell Lectin-Like Receptor Subfamily B
- Killer Cell Lectin Like Receptor Subfamily B
NK Cell Lectin-Like Receptor Subfamily B, Member 1- NK Cell Lectin-Like Receptor Subfamily B, Member 1
- NK Cell Lectin Like Receptor Subfamily B, Member 1
- NKR-P1 Receptor
- NKR P1 Receptor
- Receptor, NKR-P1
- NKR-P1 Receptors
- NKR P1 Receptors
- Receptors, NKR-P1
- Receptors, NKR P1
- CD161 Antigen
- Antigen, CD161
- Antigens, CD161
- CD161 Antigens
|
Below are MeSH descriptors whose meaning is more general than "NK Cell Lectin-Like Receptor Subfamily B".
Below are MeSH descriptors whose meaning is more specific than "NK Cell Lectin-Like Receptor Subfamily B".
This graph shows the total number of publications written about "NK Cell Lectin-Like Receptor Subfamily B" by people in this website by year, and whether "NK Cell Lectin-Like Receptor Subfamily B" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "NK Cell Lectin-Like Receptor Subfamily B" by people in Profiles.
-
A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. Blood. 2017 02 09; 129(6):740-758.
-
Requirement for innate immunity and CD90? NK1.1? lymphocytes to treat established melanoma with chemo-immunotherapy. Cancer Immunol Res. 2015 Mar; 3(3):296-304.
-
Desiccating stress-induced chemokine expression in the epithelium is dependent on upregulation of NKG2D/RAE-1 and release of IFN-? in experimental dry eye. J Immunol. 2014 Nov 15; 193(10):5264-72.
-
Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells. J Immunol. 2004 Apr 15; 172(8):4762-9.
-
NKT and T cells: coordinate regulation of NK-like phenotype and cytokine production. Eur J Immunol. 2002 Dec; 32(12):3453-62.
-
Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses. J Natl Cancer Inst. 2001 Jul 04; 93(13):998-1007.
-
Splenic NK1.1-negative, TCR alpha beta intermediate CD4+ T cells exist in naive NK1.1 allelic positive and negative mice, with the capacity to rapidly secrete large amounts of IL-4 and IFN-gamma upon primary TCR stimulation. J Immunol. 1999 May 01; 162(9):5156-63.
-
Beta 2-microglobulin-dependent NK1.1+ T cells are not essential for T helper cell 2 immune responses. J Exp Med. 1996 Oct 01; 184(4):1295-304.